{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-25-000055","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.418653+00:00","generated_at":"2026-05-17T01:18:20.561683+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Travere reports Q3 net income of $25.7M; FILSPARI sales up 155% YoY to $90.9M","bullets":["U.S. FILSPARI net product sales $90.9M (+155% YoY); 731 new patient start forms in Q3.","Total revenue $164.9M incl. $40M milestone from CSL Vifor; net income $25.7M ($0.29 basic EPS) vs net loss of $54.8M in Q3 2024.","Remaining $68.9M of 2025 convertible notes retired; cash & equivalents $254.5M as of Sep 30 (excl. October milestone).","FDA sNDA for FILSPARI in FSGS under review; PDUFA target Jan 13, 2026; no advisory committee needed.","REMS modified removing embryo-fetal toxicity monitoring; KDIGO guidelines recommend FILSPARI as first-line therapy in IgAN."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-25-000055","json":"https://secwatch.observer/filing/0001438533-25-000055.json","markdown":"https://secwatch.observer/filing/0001438533-25-000055.md","text":"https://secwatch.observer/filing/0001438533-25-000055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853325000055/0001438533-25-000055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853325000055/tvtx-20251030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:18:20.561683+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}